Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

BR.29 -- A double-blind randomized trial of Cediranib versus placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer -- was centrally activated November 6, 2008.
http://www.ctg.queensu.ca/trials/lung/br29/br29.html